0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      METTL5 promotes cell proliferation, invasion, and migration by up-regulating Toll-like receptor 8 expression in colorectal cancer

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          BACKGROUND

          N6-methyladenosine (m6A) modification represents the predominant alteration found in eukaryotic messenger RNA and plays a crucial role in the progression of various tumors. However, despite its significance, the comprehensive investigation of METTL5, a key m6A methyltransferase, in colorectal cancer (CRC) remains limited.

          AIM

          To investigate the role of METTL5 in CRC.

          METHODS

          We assessed METTL5 expression levels in clinical samples obtained from CRC patients as well as in CRC cell lines. To elucidate the downstream targets of METTL5, we performed RNA-sequencing analysis coupled with correlation analysis, leading us to identify Toll-like receptor 8 (TLR8) as a potential downstream target. In vitro functional assessments of METTL5 and TLR8 were conducted using CCK-8 assays, scratch assays, as well as assays measuring cell migration and invasion.

          RESULTS

          Our findings reveal a pronounced upregulation of METTL5 expression in both CRC cells and tissues, which correlated significantly with an unfavorable prognosis. In vitro experiments unequivocally demonstrated the oncogenic role of METTL5, as evidenced by its promotion of CRC cell proliferation, invasion, and migration. Notably, we identified TLR8 as a downstream target of METTL5, and subsequent down-regulation of TLR8 led to a significant inhibition of CRC cell proliferation, invasion, and tumor growth.

          CONCLUSION

          The heightened expression of METTL5 in CRC is strongly associated with clinicopathological features and a poor prognosis, thereby underscoring its potential utility as a critical marker for facilitating early diagnosis and prognostication in CRC.

          Related collections

          Most cited references29

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

          Summary Background Data about the global, regional, and country-specific variations in the levels and trends of colorectal cancer are required to understand the impact of this disease and the trends in its burden to help policy makers allocate resources. Here we provide a status report on the incidence, mortality, and disability caused by colorectal cancer in 195 countries and territories between 1990 and 2017. Methods Vital registration, sample vital registration, verbal autopsy, and cancer registry data were used to generate incidence, death, and disability-adjusted life-year (DALY) estimates of colorectal cancer at the global, regional, and national levels. We also determined the association between development levels and colorectal cancer age-standardised DALY rates, and calculated DALYs attributable to risk factors that had evidence of causation with colorectal cancer. All of the estimates are reported as counts and age-standardised rates per 100 000 person-years, with some estimates also presented by sex and 5-year age groups. Findings In 2017, there were 1·8 million (95% UI 1·8–1·9) incident cases of colorectal cancer globally, with an age-standardised incidence rate of 23·2 (22·7–23·7) per 100 000 person-years that increased by 9·5% (4·5–13·5) between 1990 and 2017. Globally, colorectal cancer accounted for 896 000 (876 300–915 700) deaths in 2017, with an age-standardised death rate of 11·5 (11·3–11·8) per 100 000 person-years, which decreased between 1990 and 2017 (−13·5% [–18·4 to −10·0]). Colorectal cancer was also responsible for 19·0 million (18·5–19·5) DALYs globally in 2017, with an age-standardised rate of 235·7 (229·7–242·0) DALYs per 100 000 person-years, which decreased between 1990 and 2017 (−14·5% [–20·4 to −10·3]). Slovakia, the Netherlands, and New Zealand had the highest age-standardised incidence rates in 2017. Greenland, Hungary, and Slovakia had the highest age-standardised death rates in 2017. Numbers of incident cases and deaths were higher among males than females up to the ages of 80–84 years, with the highest rates observed in the oldest age group (≥95 years) for both sexes in 2017. There was a non-linear association between the Socio-demographic Index and the Healthcare Access and Quality Index and age-standardised DALY rates. In 2017, the three largest contributors to DALYs at the global level, for both sexes, were diet low in calcium (20·5% [12·9–28·9]), alcohol use (15·2% [12·1–18·3]), and diet low in milk (14·3% [5·1–24·8]). Interpretation There is substantial global variation in the burden of colorectal cancer. Although the overall colorectal cancer age-standardised death rate has been decreasing at the global level, the increasing age-standardised incidence rate in most countries poses a major public health challenge across the world. The results of this study could be useful for policy makers to carry out cost-effective interventions and to reduce exposure to modifiable risk factors, particularly in countries with high incidence or increasing burden. Funding Bill & Melinda Gates Foundation.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study

              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer

              A priority in cancer research is to innovate therapies that are not only effective against tumor progression but also address comorbidities such as cachexia that limit quality and quantity of life. We demonstrate that TLR7/8 agonist R848 induces anti-tumor responses and attenuates cachexia in murine models of pancreatic ductal adenocarcinoma (PDAC). In vivo, tumors from two of three cell lines were R848-sensitive, resulting in smaller tumor mass, increased immune complexity, increased CD8+ T-cell infiltration and activity, and decreased Treg frequency. R848-treated mice demonstrated improvements in behavioral and molecular cachexia manifestations, resulting in a near-doubling of survival duration. Knockout mouse studies revealed that stromal, not neoplastic, TLR7 is requisite for R848-mediated responses. In patient samples, we found Tlr7 is ubiquitously expressed in stroma across all stages of pancreatic neoplasia, but epithelial Tlr7 expression is relatively uncommon. These studies indicate immune-enhancing approaches including R848 may be useful in PDAC and cancer-associated cachexia.
                Bookmark

                Author and article information

                Contributors
                Journal
                World J Gastrointest Oncol
                WJGO
                World Journal of Gastrointestinal Oncology
                Baishideng Publishing Group Inc
                1948-5204
                15 May 2024
                15 May 2024
                : 16
                : 5
                : 2006-2017
                Affiliations
                Department of General Surgery, The Second Affiliated Hospital of Anhui Medical University, Hefei 230001, Anhui Province, China
                Department of Vascular Surgery, The Second Affiliated Hospital of Anhui Medical University, Hefei 230002, Anhui Province, China
                Department of General Surgery, The Second Affiliated Hospital of Anhui Medical University, Hefei 230001, Anhui Province, China
                Department of Vascular Surgery, The Second Affiliated Hospital of Anhui Medical University, Hefei 230002, Anhui Province, China
                Department of General Surgery, The Second Affiliated Hospital of Anhui Medical University, Hefei 230001, Anhui Province, China
                Department of Vascular Surgery, The Second Affiliated Hospital of Anhui Medical University, Hefei 230002, Anhui Province, China
                Department of General Surgery, The Second Affiliated Hospital of Anhui Medical University, Hefei 230001, Anhui Province, China
                Department of Vascular Surgery, The Second Affiliated Hospital of Anhui Medical University, Hefei 230002, Anhui Province, China
                Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei 230001, Anhui Province, China
                Anhui Public Health Clinical Center, Hefei 230012, Anhui Province, China
                Department of Scientific Research, Anhui Public Health Clinical Center, Hefei 230012, Anhui Province, China
                Department of Scientific Research, The First Affiliated Hospital of Anhui Medical University, Hefei 230001, Anhui Province, China. 472959583@ 123456qq.com
                Author notes

                Co-corresponding authors: Wen-Bin Wang and Xue Zhao.

                Author contributions: Kong LS, Tao R, and Li YF collected the data, performed the experiments and statistical analysis, and wrote the manuscript; Wang WB and Zhao X designed the study and performed quality control. Kong LS and Tao R contributed equally to this work. Wang WB and Zhao X made outstanding contributions to this study as co-corresponding authors.

                Supported by Natural Science Foundation in Anhui Province of China, No. 2008085MH279; and Key Project of Anhui Translational Medicine Research Institute, No. 2022zhyx-B08.

                Corresponding author: Xue Zhao, MM, Department of Scientific Research, Anhui Public Health Clinical Center, No. 100 Huaihai Avenue, Hefei 230012, Anhui Province, China. 472959583@ 123456qq.com

                Article
                jWJGO.v16.i5.pg2006 88145
                10.4251/wjgo.v16.i5.2006
                11099443
                38764815
                bedfa09c-3bec-4e45-bbad-e4f12ce9396d
                ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

                This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.

                History
                : 13 September 2023
                : 10 January 2024
                : 18 March 2024
                Categories
                Basic Study

                mettl5,toll-like receptor 8,colorectal cancer
                mettl5, toll-like receptor 8, colorectal cancer

                Comments

                Comment on this article